한빛사논문
- 조회322
Kyuyeon Cho 1, Seoyeon Park 1, Eun-Young Kim 2, Ai Koyanagi 3 4, Louis Jacob 4 5, Dong K Yon 6, Seung Won Lee 7, Min Seo Kim 8, Joaquim Radua 9 10 11 12, Dragioti Elena 13, Jae Il Shin 14, Lee Smith 15
1Yonsei University College of Medicine, Seoul, Republic of Korea.
2Evidence-Based and Clinical Research Laboratory, Department of Health, Social and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea.
3ICREA, Pg. Lluis Companys 23, Barcelona, Spain.
4Research and Development Unit, Parc Sanitari Sant Joan de Déu, CIBERSAM, Barcelona, Spain.
5Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.
6Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
7Department of Data Science, Sejong University College of Software Convergence, Seoul, Republic of Korea.
8Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul, Republic of Korea.
9Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Early Psychosis: Interventions and Clinical-detection (EPIC) Lab, London, UK.
10Mental Health Networking Biomedical Research Centre (CIBERSAM), Barcelona, Spain.
11Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institute, Stockholm, Sweden.
12Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
13Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linköping University, Sweden.
14Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.
15Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
Kyuyeon Cho, Seoyeon Park, and Eun-Young Kim contributed equally to this study as cofirst authors.
CORRESPONDING AUTHOR : Jae Il Shin
Abstract
It remains unclear how effective COVID-19 vaccinations will be in patients with weakened immunity due to diseases, transplantation, and dialysis. We conducted a systematic review comparing the efficacy of COVID-19 vaccination in patients with solid tumor, hematologic malignancy, autoimmune disease, inflammatory bowel disease, and patients who received transplantation or dialysis. A literature search was conducted twice using the Medline/PubMed database. As a result, 21 papers were included in the review, and seropositivity rate was summarized by specific type of disease, transplantation, and dialysis. When different papers studied the same type of patient group, a study with a higher number of participants was selected. Most of the solid tumor patients showed a seropositivity rate of more than 80% after the second inoculation, but a low seropositivity was found in certain tumors such as breast cancer. Research in patients with certain types of hematological malignancy and autoimmune diseases has also reported low seropositivity, and this may have been affected by the immunosuppressive treatment these patients receive. Research in patients receiving dialysis or transplantation has reported lower seropositivity rates than the general population, while all patients with inflammatory bowel disease have converted to be seropositive. Meta-analysis validating these results will be needed, and studies will also be needed on methods to protect patients with reduced immunity from COVID-19.
논문정보
- Research article
- 2022년 09월 (BRIC 등록일 2022-11-21)
- 국내(교신)+국외 연구진
- 의약학 > 인체시스템의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
